EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access

Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures

Oğuzhan Korkmaz, Ömer Serdar Hakyemez, Niyazi Çakır, Ardahan Özdenboyacı, İbrahim Uzunlu, Abdullah Demirtaş, İbrahim Azboy

Acta Orthopaedica et Traumatologica Turcica · 27.03.2026 · 60 (2)

DOI: 10.5152/j.aott.2026.25305 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Acta Orthopaedica et Traumatologica Turcica, online erschienen am 27.03.2026. Verfasst von Oğuzhan Korkmaz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics and Traumatology, Sakarya Research and Training Hospital, Sakarya University, Sakarya, Türkiye. Hauptthemen laut MEDLINE: Enoxaparin, Aspirin, Venous Thromboembolism, Hip Fractures. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The risk of symptomatic venous thromboembolism (VTE) following hip fracture surgery is estimated at 1%-6%, necessitating effective prophylactic measures. While aspirin has been widely used in total hip and knee arthroplasty due to its comparable efficacy, reduced bleeding risk, and cost-effectiveness, its role in trauma patients remains under researched. This study aims to evaluate the efficacy and safety of aspirin and enoxaparin for VTE prophylaxis in hip fracture patients.

Methods

This two-center, retrospective study analyzed 306 adult patients who underwent hip fracture surgery between 2019 and 2023. Patients were divided into 2 groups: the aspirin group (81 mg twice daily) and the enoxaparin group (40 mg subcutaneous once daily), both receiving prophylaxis for 4 weeks postoperatively. Demographics, comorbidities, surgical details, and clinical outcomes—including major bleeding events, symptomatic VTE (deep vein thrombosis and pulmonary embolism), periprosthetic joint infection (PJI), blood transfusion requirements, and 90-day mortality—were recorded. Statistical analyses were performed using Pearson chi-square and independent t-tests, with significance set at P < .05.

Results

The aspirin group (n = 136) and enoxaparin group (n = 170) had mean ages of 67.66 Å} 19.67 and 63.42 Å} 19.71 years, respectively. Hemoglobin decrease was significantly lower in the aspirin group (1.75 Å} 1.07 g/dL vs. 2.73 Å} 1.56 g/dL, P = .001). In addition, the amount of postoperative blood transfusion was statistically significantly lower in the aspirin group compared to in the enoxaparin group (0.89 vs. 1.31 units, respectively, P = .034). There was no significant difference in mean hospital stay (6.84 vs. 6.65 days, P = .751). The incidence of major bleeding was higher in the enoxaparin group (3.7% (n = 5) vs. 5.3% (n = 9)), though not statistically significant (P = .789). Symptomatic VTE occurred in 3.7% (n = 5) of the aspirin group and 5.3% (n = 9) of the enoxaparin group (P = .453). Periprosthetic joint infection was observed in 2 patients in the enoxaparin group but none in the aspirin group (P = .447). Mortality within 90 days was lower in the aspirin group (8.8% (n = 12) vs. 15.9% (n = 27)), but the difference was not statistically significant (P = .066).

Conclusion

This study suggests that aspirin appears to be a reasonable alternative to enoxaparin for VTE prophylaxis in hip fracture patients, demonstrating comparable efficacy with a lower blood transfusion requirement and similar rates of major bleeding and symptomatic VTE. Given its affordability, ease of administration, and favorable safety profile, aspirin appears to be a reasonable and costeffective alternative for high-risk trauma patients. Cite this article as: Korkmaz O, Hakyemez ÖS, Çakır N, et al. Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures. Acta Orthop Traumatol Turc. 2026; 60(2), 0305, doi: 10.5152/j.aott.2026.25305.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinAspirinVenous ThromboembolismHip FracturesPostoperative ComplicationsAnticoagulantsHumansFemaleAgedMaleRetrospective StudiesMiddle AgedTreatment OutcomeArthroplasty, Replacement, HipAged, 80 and over

Substanzen

EnoxaparinAspirinAnticoagulants

Autor:innen und Institutionen

  • Department of Orthopaedics and Traumatology, Sakarya Research and Training Hospital, Sakarya University, Sakarya, Türkiye.
  • Department of Orthopaedics and Traumatology, Şırnak State Hospital, Şırnak, Türkiye.
  • Department of Orthopaedics and Traumatology, İstanbul Medipol University, İstanbul, Türkiye.
  • İstanbul Medipol University, İstanbul, Türkiye.
  • Department of Orthopaedics and Traumatology, İstanbul Medeniyet University, İstanbul, Türkiye.

Zitieren

APA

Korkmaz, O., Hakyemez, Ö. S., Çakır, N., Özdenboyacı, A., Uzunlu, İ., Demirtaş, A., & Azboy, İ. (2026). Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures. Acta Orthopaedica et Traumatologica Turcica, 60(2). https://doi.org/10.5152/j.aott.2026.25305

Vancouver

Korkmaz O, Hakyemez ÖS, Çakır N, Özdenboyacı A, Uzunlu İ, Demirtaş A, et al. Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures. Acta Orthopaedica et Traumatologica Turcica. 2026;60(2). doi:10.5152/j.aott.2026.25305

BibTeX
@article{Korkmaz2026,
  author = {Korkmaz, Oğuzhan and Hakyemez, Ömer Serdar and Çakır, Niyazi and Özdenboyacı, Ardahan and Uzunlu, İbrahim and Demirtaş, Abdullah and Azboy, İbrahim},
  title = {Comparison of clinical outcomes of enoxaparin and aspirin for postoperative venous thromboembolism prophylaxis in hip fractures},
  journal = {Acta Orthopaedica et Traumatologica Turcica},
  year = {2026},
  volume = {60},
  number = {2},
  doi = {10.5152/j.aott.2026.25305}
}
Kostenlos starten →